Linoladiol N (Estradiol Hemihydrate)

Estradiol hemihydrate binds to estrogen receptors in target cells, forming a complex that regulates gene transcription. This modulates the growth and function of reproductive tissues, bone, and cardiovascular systems, producing the therapeutic estrogenic effects needed for hormone replacement.

The specific dose and regimen of Linoladiol N are determined by the prescribing clinician based on the patient’s condition, age, and response to therapy. Dosage details are provided in the product’s prescribing information and should not be altered without medical guidance.

Estradiol hemihydrate is generally contraindicated during pregnancy because excess estrogen can affect fetal development. It is also not recommended while breastfeeding, as it may pass into breast milk and influence infant hormone balance. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Linoladiol N delivers estradiol hemihydrate via the vaginal route, offering localized therapy with lower systemic exposure compared with oral or transdermal estrogens. This can result in fewer hepatic side effects and more direct relief of vaginal atrophy, while still providing systemic estrogen benefits.

Linoladiol N should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain potency and stability throughout its shelf life.

Linoladiol N is applied intravaginally according to the prescribing information. The patient inserts the tablet or insert into the vagina using a clean applicator or fingertip, typically once daily or as directed by the healthcare provider.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, myocardial infarction, and the potential for endometrial hyperplasia or carcinoma with prolonged use. Patients should be monitored for signs of clotting, severe headache, or abnormal uterine bleeding.

Linoladiol N is contraindicated in women with active estrogen‑dependent cancers (e.g., breast, ovarian, uterine), unexplained vaginal bleeding, known thromboembolic disorders, severe liver disease, or a history of severe allergic reactions to estradiol or formulation excipients.